Q32 Bio (STU:DB0) 3-Year EBITDA Growth Rate: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:DB0 Q32 Bio Inc STU:DB0
17 GF Score
Price €10.21
! 3 Warning Signs
View Full Analysis

What is Q32 Bio 3-Year EBITDA Growth Rate?

Q32 Bio STU:DB0 -6.24% 17 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates STU:DB0 with a GF Score™ of 17/100. The stock has 3 warning signs investors should review. Among 1,128 Biotechnology companies, Q32 Bio ranks worse than 88652.39% on this metric.

Q32 Bio's EBITDA per Share for the three months ended in Jun. 2026 was €-0.39.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Q32 Bio was -14.50% per year. The lowest was -14.50% per year. And the median was -14.50% per year.

Q32 Bio  (STU:DB0) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Q32 Bio 3-Year EBITDA Growth Rate Related Terms

STU:DB0 vs OCGN, RZLT, PRLD: 3-Year EBITDA Growth Rate Comparison

For the Biotechnology subindustry, Q32 Bio's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Q32 Bio 3-Year EBITDA Growth Rate vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Q32 Bio's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Q32 Bio's 3-Year EBITDA Growth Rate falls into.


STU:DB0
17GF Score
Q32 Bio Inc STU:DB0
3-Year EBITDA Growth Rate is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Q32 Bio 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Q32 Bio (STU:DB0) has a 3-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Q32 Bio and its competitors. According to the industry distribution chart, Q32 Bio ranks #999999 out of 1128 companies in the Biotechnology industry.
Is Q32 Bio's 3-Year EBITDA Growth Rate too high?
Q32 Bio's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Q32 Bio ranks #999999 out of 1128 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Q32 Bio has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Q32 Bio's 3-Year EBITDA Growth Rate compare to OCGN and RZLT?
According to the Biotechnology industry distribution chart, Q32 Bio ranks #999999 out of 1128 companies for 3-Year EBITDA Growth Rate. This places Q32 Bio in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.65, based on 1,128 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Q32 Bio and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q32 Bio's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q32 Bio stock overvalued right now?
Q32 Bio (STU:DB0) has a current 3-Year EBITDA Growth Rate of 0.00%. The current 3-Year EBITDA Growth Rate is 0.00%. Q32 Bio's overall GF Score™ is 17/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Q32 Bio (STU:DB0), the current 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Q32 Bio Business Description

Other Exchanges QTTB:USADB0:Germany
Address 830 Winter Street, Waltham, MA, USA, 02451
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
17GF Score

Get the complete analysis for STU:DB0

3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.21
Price